Evidence map›Paper›PMID 32431704›Full record

ArticleFrontiers in immunology2020

A Polymorphism Within the

Laura Espino-Paisán, Teresa Agudo-Jiménez, Isabel Rosales-Martínez, Pilar López-Cotarelo, María Ángel García-Martínez, María Inmaculada Domínguez-Mozo, Silvia Pérez-Pérez, Romina Dieli-Crimi, Manuel Comabella, Elena Urcelay and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Laura Espino-PaisánLaboratorio de Investigación en Genética de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Teresa Agudo-JiménezLaboratorio de Investigación en Genética de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Isabel Rosales-MartínezLaboratorio de Investigación en Genética de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Pilar López-CotareloLaboratorio de Investigación en Genética de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
María Ángel García-MartínezGrupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
María Inmaculada Domínguez-MozoGrupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Silvia Pérez-PérezGrupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Romina Dieli-CrimiServicio de Inmunología, Hospital Universitari Vall d'Hebron (HUVH), Diagnostic Immunology, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Manuel ComabellaServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain.
Elena UrcelayLaboratorio de Investigación en Genética de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Roberto Álvarez-LafuenteGrupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelin basic protein (MBP) is thought to be one of the key autoantigens in multiple sclerosis (MS) development. A recent study described the association of the single nucleotide polymorphism (SNP) rs12959006, within the

Indexed as

Polymorphism, Single NucleotideAdultEpstein-Barr Virus InfectionsFemaleFollow-Up StudiesGenotypeHerpesvirus 4, HumanHerpesvirus 6, HumanHumansMaleMultiple Sclerosis, Relapsing-RemittingMyelin Basic ProteinPrognosisRecurrenceRetrospective StudiesRoseolovirus InfectionsMBP protein, humanMyelin Basic Proteingenetic markerHHV-6multiple sclerosismyelin basic proteinrelapsesex differencesSNP

Identifiers

PMID32431704
PMCPMC7214696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.